Q-omics provides the consensus-scored CDK14 profile across patient tissues and cancer cell-line models. CDK14 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDK14 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CDK14 protein abundance shows 21,879 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where CDK14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK14 survival associations across molecular data types. CDK14 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK14 RNA expression–survival associations across cancer types. High CDK14 expression shows unfavorable associations in STAD and BLCA, but favorable associations in KIRC, UCS, BRCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDK14 RNA expression.
This table summarizes CDK14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CDK14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK14 shows lower tumor expression in LUAD, UCEC and THCA and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher CDK14 RNA expression in tumor versus normal tissue (log2 FC = +1.736, t-test p < 0.001).
This table shows molecular features associated with CDK14 in patient tissues and cancer cell lines. In patient samples, CDK14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
